Trial of pRehospital Intervention With trAditional Chinese Medicine for Acute strokE
NCT ID: NCT04275349
Last Updated: 2020-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2020-03-20
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Xingnaojing for Mild-to-severe Acute Ischemic Stroke
NCT04150835
Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke
NCT05559307
Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)
NCT02728180
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
NCT04415164
Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke
NCT02967484
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure group(continuously)
xingnaojing injection will be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital or at hospital)
Xingnaojing injection within 24 hours of symptom onset
intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
Exposure group(uncontinuously)
xingnaojing injection will be intravenously administered within 24 hours of symptom onset for once (on prehospital ambulance )
Xingnaojing injection within 24 hours of symptom onset
intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
Completely unexposed group
xingnaojing injection will not be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital)
No interventions assigned to this group
Incompletely unexposed group
xingnaojing injection will not be intravenously administered on ambulance but administered more than 24 hours of symptom onset at hospital
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xingnaojing injection within 24 hours of symptom onset
intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptom onset within 24 hours；
* Age ≥ 18 .
Exclusion Criteria
* Other conditions that render outcomes or follow-up unlikely to be assessed; Known to be pregnant or breastfeeding;
* Non-acute stroke (result from Computed Tomography(CT) or Magnetic Resonance Imaging(MRI)).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Emergency Medical Center
OTHER
Beijing Tiantan Hospital
OTHER
Beijing Hospital of Traditional Chinese Medicine
OTHER
Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine
UNKNOWN
Xuanwu Hospital, Beijing
OTHER
Beijing Friendship Hospital
OTHER
Beijing Chao Yang Hospital
OTHER
Beijing Shijitan Hospital, Capital Medical University
OTHER
Beijing Fengtai Youanmen Hospital
UNKNOWN
Beijing Jiangong Hospital
UNKNOWN
Beijing Chaoyang Emergency Medical Center
UNKNOWN
Beijing Chaoyang Integrative Medicine Emergency Medical Center
UNKNOWN
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
OTHER
Fangshan Hospital，Beijing University of Chinese Medicine
UNKNOWN
Civil Aviation General Hospital
OTHER
The First Hospital of Fangshan District,Beijing
OTHER
Beijing Chinese Medicine Hospital-Pinggu Hospital
UNKNOWN
Beijing Pinggu District Hospital
OTHER
Dongzhimen Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ying Gao
President of the Institute for Encephalopathy, Beijing University of Chinese Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ying Gao, MD
Role: PRINCIPAL_INVESTIGATOR
Dongzhimen Hospital, Beijing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dongzhimen Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chen Y, Tian Z, Wang S, Liu H, Liu Y, Peng W, Lai X, Qi D, Kong L, Gao Y. Trial of a prehospital intervention with traditional Chinese medicine for acute stroke (TRACE): Protocol for a mixed-methods research study. Front Pharmacol. 2022 Aug 29;13:879282. doi: 10.3389/fphar.2022.879282. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFH 2018-1-4191
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.